Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more
here
.
About Us
About hVIVO
Leadership Team
Our Companies
Key Stats
History
Services
Challenge Trials
RSV
Influenza
COVID-19
HRV
Malaria
Asthma & COPD
Laboratory Services
Assay Development
Field Trial Bio-logistics
Cell Based Assays
Molecular Services
Compound Efficacy & VRM
Biomarker Analysis
Phase II-III Clinical Trials
Vaccine Phase II-III Trials
Articles & Research
News & Media
Regulatory News
Media Coverage
Media Press Kit
Video Library
Events
Investors
New
Investors
Regulatory News & Email Alerts
Results Centre
Share Price Information
Events & Presentations
Environmental, Social & Governance
AIM Rule 26
Advisors
Documents
Corporate Governance
Volunteers
Careers
Contact Us
Contact Us
12 May 2022
Go Back
Human infection studies: Key considerations for challenge agent development and production
Share this:
Other recent posts
Article
Human Clinical Trials: A Tool in the Fight Against Infectious Diseases
International Clinical Trials, Autumn 2022, pages 94-97. © Samedan Ltd
View Link
Presentation
RSV Vaccines/Prophylactics: Key learning from the RSV challenge model and efficacy of vaccines
View Link
If you’re a potential customer, job seeker, health professional or an investor, find out how hVIVO can help you.
Contact hVIVO
twitter
facebook
envelope
linkedin
angle-down
xing
paper-plane
pinterest-p
whatsapp
commenting
meetup
chevron-down